Contract Bio- Manufacturing Slated to Grow Significantly

Page Views: 3

Frost and Sullivan, the global market guru, suggests that Contract Bio-Manufacturing is likely to grow at a CAGR of 60% between now and 2019. The growth will be due to the fact that many ($60Billion worth) of pharmaceutical patents will be expiring over the period. Given the costs and risks associated with starting or re-purposing manufacturing lines in the pharma industry, pharma manufacturers who wish to capitalize on producing lower-cost generics will resort to going with Contract Manufacturers.  More


Leave a Comment

Your email address will not be published. Required fields are marked *

Attendee Request Form: 2023 Hardware Prototyping Workshop
Thanks for your interest in this resource, fill out the information below to download.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.